Also trades as: 0K1R.L (LSE) · $vol 0M
VRDN NASDAQ
Viridian Therapeutics, Inc.
1W: +1.5%
1M: +23.4%
3M: -35.5%
YTD: -42.3%
1Y: +28.0%
3Y: -24.5%
5Y: +1.6%
$17.24
-0.45 (-2.54%)
Weekly Expected Move ±18.1%
$11
$14
$17
$20
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (77)
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Therapeutics prices upsized $350M concurrent stock, and convertible notes offerings
12 Health Care Stocks Moving In Tuesday's Intraday Session
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Viridian Therapeutics GAAP EPS of -$0.90 beats by $0.19, revenue of $0.14M beats by $0.11M
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
Why Is Viridian Therapeutics Stock Sinking Monday?
12 Health Care Stocks Moving In Monday's Intraday Session
Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints
VRDN Jul 2026 22.000 put (VRDN260717P00022000) Stock Historical Prices & Data - Yahoo! Finance Canada
Income Statement - Intellectia AI
A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results - simplywall.st
VRDN Apr 2026 5.000 put (VRDN260417P00005000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart Data - What's Changed - Sahm
VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal? - Stocktwits
DRI Healthcare Trust Price Target Raised to $22.00 at Stifel Canada
Are Viridian Therapeutics' (VRDN) REVEAL-1 Results Enough To Redefine Its TED Competitive Position? - Yahoo Finance
Are Viridian Therapeutics' (VRDN) REVEAL-1 Results Enough To Redefine Its TED Competitive Position?
Viridian Therapeutics (VRDN) Target Price Lowered by Evercore IS - GuruFocus
What is HC Wainwright's Estimate for VRDN FY2027 Earnings? - MarketBeat
Discipline and Rules-Based Execution in VRDN Response - Stock Traders Daily
FuboTV and Yext are the most oversold among U.S. small-cap stocks
VRDN Oct 2026 22.000 put (VRDN261016P00022000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly - Seeking Alpha
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co. - MarketBeat
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday
Viridian tumbles on positive data for key eye drug prospect
Stocks to watch on Monday after market: VRDN, BSX, MTB, AL
Stocks to watch on Monday after market: VRDN, BSX, MTB, AL (SPY:NYSEARCA) - Seeking Alpha
Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results
Why This Amgen Rival Just Plummeted By A Third - Investor's Business Daily
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease
12 Health Care Stocks Moving In Monday's Intraday Session
Viridian Therapeutics shares fall over 30% after trial data disappoints
Crude Oil Rises Over 2%; US Dallas Fed Manufacturing Index Declines In March
Viridian Therapeutics’ stock sinks despite positive Phase III TED data
Top Midday Stories: Trump Touts Talks With New Iranian Regime, Renews Threats; Sysco to Acquire Jetro for $29.1 Billion
Viridian Therapeutics’ stock sinks despite positive Phase III TED data - Clinical Trials Arena
Viridian Therapeutics Shares Jump as REVEAL-1 Phase 3 Hits Primary Endpoint in Thyroid Eye Disease
$VRDN stock is down 33% today. Here's what we see in our data. - quiverquant.com
Dow Gains 200 Points; Bullfrog AI Shares Jump
Why Is Viridian Therapeutics Stock Falling Monday?
12 Health Care Stocks Moving In Monday's Pre-Market Session
Viridian Therapeutics stock tumbles despite trial success - Investing.com
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
Is It Time To Reassess Viridian Therapeutics (VRDN) After Its Strong 1-Year Share Price Run? - simplywall.st
Is It Too Late To Consider Viridian Therapeutics (VRDN) After Its 82% One-Year Surge?
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
VR Adviser Adds Over 1 Million Savara Shares
VR Adviser Adds Over 1 Million Savara Shares
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders
Viridian Therapeutics misses Q4 estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Campbell & CO Investment Adviser LLC Takes Position in Viridian Therapeutics, Inc. $VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of “Moderate Buy” from Brokerages
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fisher Asset Management LLC Lowers Stake in Viridian Therapeutics, Inc. $VRDN